Page last updated: 2024-10-27

gabapentin and Cerebral Infarction

gabapentin has been researched along with Cerebral Infarction in 6 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).

Research Excerpts

ExcerptRelevanceReference
"To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy."9.11New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005)
"To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy."5.11New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005)
"Persistent hiccups have been reported to occur occasionally during rehabilitation hospitalizations."2.44Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature. ( Browne, BA; Schuchmann, JA, 2007)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kim, JB1
Yu, S1
Pistoia, F1
Sarà, M1
Kamiya, T1
Abe, K1
Rowan, AJ1
Ramsay, RE1
Collins, JF1
Pryor, F1
Boardman, KD1
Uthman, BM1
Spitz, M1
Frederick, T1
Towne, A1
Carter, GS1
Marks, W1
Felicetta, J1
Tomyanovich, ML1
Schuchmann, JA1
Browne, BA1
Moretti, R1
Torre, P1
Antonello, RM1
Nasuelli, D1
Cazzato, G1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451]Phase 4361 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment

(NCT00438451)
Timeframe: 58 weeks

Interventionproportion of participants (Mean)
Levetiracetam0.61
Carbamazepine0.46
Lamotrigine0.56

Percentage of Patients Remaining Seizure Free at Week 58 (Visit 6)

Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58

Interventionpercentage of participants (Number)
Levetiracetam43
Carbamazepine33
Lamotrigine38

Percentage of Patients Remaining Seizure-free at Week 30 (Visit 4)

Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30

Interventionpercentage of participants (Number)
Levetiracetam48
Carbamazepine39
Lamotrigine49

Proportion of Seizure-free Days During the Maintenance Phase for Subjects Who Enter the Maintenance Phase

(NCT00438451)
Timeframe: 52 weeks

Interventionproportion of seizure-free days (Number)
Levetiracetam0.99
Carbamazepine0.99
Lamotrigine0.99

Results of Cognitive Testing (EpiTrack© by UCB) - Score at V6

EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58

Interventionunits on a scale (Mean)
Levetiracetam26.0
Carbamazepine26.0
Lamotrigine25.4

The Absolute Seizure Frequency During the Maintenance Phase (Weeks 7 - 58)

"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks

Interventionnumber of seizures (Number)
Levetiracetam168
Carbamazepine131
Lamotrigine130

The Time (in Days) to First Break-through Seizure (From Day 1 of Treatment)

(NCT00438451)
Timeframe: over the whole duration of 58 weeks

Interventiondays (Median)
LevetiracetamNA
CarbamazepineNA
LamotrigineNA

Time to Drop Out

number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks

Interventiondays (Median)
LevetiracetamNA
Carbamazepine265
LamotrigineNA

Portland Neurotoxicity Scale (PNS) at V6

"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58

,,
Interventionunits on a scale (Mean)
Cognitive toxicity subscoreSomatomotor subscoreTotal Score
Carbamazepine27.311.438.7
Lamotrigine23.710.834.5
Levetiracetam22.210.532.7

QOLIE-31 (Quality Of Life In Epilepsy) Results at V6

The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit

,,
Interventionunits on a scale (Mean)
Seizure worryOverall quality of lifeEmotional well-beingEnergy/fatigueCognitive functioningMedication effectsSocial functioningTotal ScoreHealth Scale
Carbamazepine75.465.069.854.568.970.676.368.965.7
Lamotrigine75.067.167.459.868.072.676.769.167.5
Levetiracetam85.167.272.060.875.177.681.173.969.5

Results of Cognitive Testing (EpiTrack© by UCB) - Categories at V6

"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks

,,
Interventionparticipants (Number)
Without pathological findingsBorderlineImpaired
Carbamazepine341733
Lamotrigine311539
Levetiracetam381036

Results of Cognitive Testing (EpiTrack© by UCB) - Changes to Baseline (V0) at Week 58 (V6)

"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58

,,
Interventionparticipants (Number)
ImprovedUnchangedWorsened
Carbamazepine16568
Lamotrigine155313
Levetiracetam15616

Reviews

2 reviews available for gabapentin and Cerebral Infarction

ArticleYear
[Future neuroprotective strategies in the post-thrombolysis era--neurovascular unit protection and vascular endothelial protection].
    Rinsho shinkeigaku = Clinical neurology, 2011, Volume: 51, Issue:5

    Topics: Amines; Animals; Antipyrine; Cerebral Infarction; Cyclohexanecarboxylic Acids; Edaravone; Endotheliu

2011
Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature.
    American journal of physical medicine & rehabilitation, 2007, Volume: 86, Issue:12

    Topics: Aged; Amines; Anti-Anxiety Agents; Anticonvulsants; Cerebral Infarction; Chlorpromazine; Chronic Dis

2007

Trials

2 trials available for gabapentin and Cerebral Infarction

ArticleYear
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.
    Neurology, 2005, Jun-14, Volume: 64, Issue:11

    Topics: Aged; Aging; Amines; Anticonvulsants; Carbamazepine; Cerebral Infarction; Cyclohexanecarboxylic Acid

2005
Treatment of chronic: new perspectives.
    European journal of neurology, 1999, Volume: 6, Issue:5

    Topics: Acetates; Aged; Amines; Cerebral Infarction; Chronic Disease; Cyclohexanecarboxylic Acids; Excitator

1999

Other Studies

2 other studies available for gabapentin and Cerebral Infarction

ArticleYear
Neurological picture. Trigeminal neuralgia after pontine infarction affecting the ipsilateral trigeminal nerve.
    Journal of neurology, neurosurgery, and psychiatry, 2013, Volume: 84, Issue:8

    Topics: Amines; Analgesics, Non-Narcotic; Carbamazepine; Cerebral Infarction; Cyclohexanecarboxylic Acids; G

2013
Gabapentin therapy for ocular opsoclonus-myoclonus restores eye movement communication in a patient with a locked-in syndrome.
    Neurorehabilitation and neural repair, 2010, Volume: 24, Issue:5

    Topics: Adult; Amines; Anticonvulsants; Cerebral Infarction; Cyclohexanecarboxylic Acids; Female; Gabapentin

2010